MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma

被引：33

作者：

Facciorusso, Antonio ^{[1
]}

Licinio, Raffaele ^{[2
]}

Carr, Brian I. ^{[3
]}

Di Leo, Alfredo ^{[2
]}

Barone, Michele ^{[2
]}

机构：

[1] Univ Foggia, Osped Riuniti Foggia, Dept Med & Surg Sci, Gastroenterol Unit, Foggia, Italy

[2] Univ Bari, Dept Gastroenterol, Dept Emergency & Organ Transplantat, I-70124 Bari, Italy

[3] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Gastroenterol & Liver Dis, IL-69978 Tel Aviv, Israel

来源：

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | 2015年 / 9卷 / 07期

关键词：

HCC; liver cancer; MEK; refametinib; sorafenib; RANDOMIZED PHASE-III; PROTEIN-KINASE; OPEN-LABEL; 1ST-LINE THERAPY; ASIAN PATIENTS; BAY; 86-9766; SORAFENIB; MULTICENTER; CANCER; TRIAL;

D O I：

10.1586/17474124.2015.1040763

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Sorafenib is the only approved systemic treatment for advanced hepatocellular carcinoma patients and all the recently published randomized controlled trials on new systemic drugs have been unsuccessful. This is likely due to a lack of understanding of tumor progression, molecular drivers, and liver toxicity, as well as flaws in trial design. An important signaling pathway in hepatocarcinogenesis is the MEK cascade involved in various cellular responses, including adaptation and survival. A key role in this cascade is played by MEK, of which MEK 1/2 represent the prototypes and an interesting target for new oncological drugs. This review analyzes recent developments and future perspectives on the role of MEK inhibitors in hepatocellular carcinoma treatment.

引用

页码：993 / 1003

页数：11

共 89 条

[31] Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study [J].

Fucile, Carmen ;

Marenco, Simona ;

Bazzica, Marco ;

Zuccoli, Maria Laura ;

Lantieri, Francesca ;

Robbiano, Luigi ;

Marini, Valeria ;

Di Gion, Paola ;

Pieri, Giulia ;

Stura, Paola ;

Martelli, Antonietta ;

Savarino, Vincenzo ;

Mattioli, Francesca ;

Picciotto, Antonino .

MEDICAL ONCOLOGY, 2015, 32 (01) :1-7

[32] New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma [J].

Galmiche, Antoine ;

Chauffert, Bruno ;

Barbare, Jean-Claude .

CANCER LETTERS, 2014, 346 (02) :159-162

[33]

Godin C, 2013, ANTICANCER RES, V33, P1415

[34] A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer [J].

Haura, Eric B. ;

Ricart, Alejandro D. ;

Larson, Timothy G. ;

Stella, Philip J. ;

Bazhenova, Lyudmila ;

Miller, Vincent A. ;

Cohen, Roger B. ;

Eisenberg, Peter D. ;

Selaru, Paulina ;

Wilner, Keith D. ;

Gadgeel, Shirish M. .

CLINICAL CANCER RESEARCH, 2010, 16 (08) :2450-2457

[35] Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score [J].

Hollebecque, A. ;

Cattan, S. ;

Romano, O. ;

Sergent, G. ;

Mourad, A. ;

Louvet, A. ;

Dharancy, S. ;

Boleslawski, E. ;

Truant, S. ;

Pruvot, F. -R. ;

Hebbar, M. ;

Ernst, O. ;

Mathurin, P. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (10) :1193-1201

[36] Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study [J].

Hsu, Chih-Hung ;

Kang, Yoon Koo ;

Yang, Tsai-Shen ;

Shun, Chia-Tung ;

Shao, Yu-Yun ;

Su, Wu-Chou ;

Sandoval-Tan, Jennifer ;

Chiou, Tzeon-Jye ;

Jin, Kate ;

Hsu, Chiun ;

Cheng, Ann-Lii .

ONCOLOGY, 2013, 85 (01) :44-52

[37] Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis [J].

Huynh, H ;

Nguyen, TTT ;

Chow, KHP ;

Tan, PH ;

Soo, KC ;

Tran, E .

BMC GASTROENTEROLOGY, 2003, 3 (1)

[38] AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC) [J].

Huynh, Hung ;

Ngo, Van Chanh ;

Koong, Heng Nung ;

Poon, Donald ;

Choo, Su Pin ;

Toh, Han Chong ;

Thng, Choon Hua ;

Chow, Pierce ;

Ong, Hock Soo ;

Chung, Alexander ;

Goh, Boon Cher ;

Smith, Paul D. ;

Soo, Khee Chee .

JOURNAL OF HEPATOLOGY, 2010, 52 (01) :79-87

[39] Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy [J].

Iavarone, Massimo ;

Cabibbo, Giuseppe ;

Piscaglia, Fabio ;

Zavaglia, Claudio ;

Grieco, Antonio ;

Villa, Erica ;

Camma, Calogero ;

Colombo, Massimo ;

Sangiovanni, Angelo ;

Vavassori, Sara ;

Romeo, Raffaella ;

Di Marco, Vito ;

Craxi, Antonio ;

Borghi, Alberto ;

Granito, Alessandro ;

Bolondi, Luigi ;

Airoldi, Aldo ;

Pinzello, Giovambattista ;

Biolato, Marco ;

Racco, Simona ;

Pompili, Maurizio ;

Lei, Barbara ;

De Maria, Nicola .

HEPATOLOGY, 2011, 54 (06) :2055-2063

[40] Activation of mitogen-activated protein kinases extracellular signal-regulated kinases in human hepatocellular carcinoma [J].

Ito, Y ;

Sasaki, Y ;

Horimoto, M ;

Wada, S ;

Tanaka, Y ;

Kasahara, A ;

Ueki, T ;

Hirano, T ;

Yamamoto, H ;

Fujimoto, J ;

Okamoto, E ;

Hayashi, N ;

Hori, M .

HEPATOLOGY, 1998, 27 (04) :951-958

← 1 2 3 4 5 6 7 8 9 →